Literature DB >> 12496472

DNA repair and tumorigenesis: lessons from hereditary cancer syndromes.

Christopher D Heinen1, Christoph Schmutte, Richard Fishel.   

Abstract

The discovery that alterations of the DNA mismatch repair system (MMR) were linked to the common human cancer susceptibility syndrome hereditary nonpolyposis colon cancer (HNPCC) resulted in the declaration of a third class of genes involved in tumor development. In addition to oncogenes and tumor suppressors, alterations of DNA repair genes involved in maintaining genomic stability were found to be a clear cause of tum the level of the single nucleotides or chromosomes. This observation suggested that the establishment of genomic instability, termed the Mutator Phenotype, was an important aspect of tumor development.(1,2) Since the initial identification of the human MutS homolog hMSH2 nearly a decade ago,(3,4) more links have been described between human cancers and genes involved in maintaining genomic stability. Work in recent years has revealed that DNA repair proteins may also function in signaling pathways that provoke cell cycle arrest and apoptosis. This review will focus on the genetic and biochemical functions of DNA repair genes linked to hereditary cancer predisposition characterized by genomic instability (Table 1). Interestingly, the protein products of these genes have been directly or indirectly linked to the DNA damage-induce cell cycle arrest and apoptosis. We conclude that a robust connection between DNA repair proteins and damage-induced apoptosis may be as important for tumorigenesis as their role in maintaining genome stability.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12496472     DOI: 10.4161/cbt.1.5.160

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  40 in total

1.  MED1: a central molecule for maintenance of genome integrity and response to DNA damage.

Authors:  Barbara L Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

Review 2.  Haploinsufficiency in mouse models of DNA repair deficiency: modifiers of penetrance.

Authors:  Diane C Cabelof
Journal:  Cell Mol Life Sci       Date:  2011-09-28       Impact factor: 9.261

3.  The predicted truncation from a cancer-associated variant of the MSH2 initiation codon alters activity of the MSH2-MSH6 mismatch repair complex.

Authors:  Jennifer L Cyr; Graham D Brown; Jennifer Stroop; Christopher D Heinen
Journal:  Mol Carcinog       Date:  2011-08-11       Impact factor: 4.784

Review 4.  Mismatch repair defects and Lynch syndrome: The role of the basic scientist in the battle against cancer.

Authors:  Christopher D Heinen
Journal:  DNA Repair (Amst)       Date:  2015-12-02

5.  Functional interrogation of Lynch syndrome-associated MSH2 missense variants via CRISPR-Cas9 gene editing in human embryonic stem cells.

Authors:  Abhijit Rath; Akriti Mishra; Victoria Duque Ferreira; Chaoran Hu; Gregory Omerza; Kevin Kelly; Andrew Hesse; Honey V Reddi; James P Grady; Christopher D Heinen
Journal:  Hum Mutat       Date:  2019-08-17       Impact factor: 4.878

Review 6.  The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside.

Authors:  C Richard Boland; Minoru Koi; Dong K Chang; John M Carethers
Journal:  Fam Cancer       Date:  2007-07-17       Impact factor: 2.375

7.  The frequency and structure of recombinant products is determined by the cellular level of MutL.

Authors:  Marina Elez; Miroslav Radman; Ivan Matic
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-14       Impact factor: 11.205

8.  Ovarian cancer and DNA repair: DNA ligase IV as a potential key.

Authors:  Joana Assis; Deolinda Pereira; Rui Medeiros
Journal:  World J Clin Oncol       Date:  2013-02-10

9.  Mutation analysis of Rad18 in human cancer cell lines and non small cell lung cancer tissues.

Authors:  Tadahiko Nakamura; Shinji Ishikawa; Yoshikatsu Koga; Youhei Nagai; Yu Imamura; Kouei Ikeda; Takeshi Mori; Hiroaki Nomori; Hideo Baba
Journal:  J Exp Clin Cancer Res       Date:  2009-07-25

10.  Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

Authors:  Ruth Plummer; Christopher Jones; Mark Middleton; Richard Wilson; Jeffrey Evans; Anna Olsen; Nicola Curtin; Alan Boddy; Peter McHugh; David Newell; Adrian Harris; Patrick Johnson; Heidi Steinfeldt; Raz Dewji; Diane Wang; Lesley Robson; Hilary Calvert
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.